Skip to content

Study · In vitro (cells) · 2013

1 result

Adiponectin attenuates angiotensin II-induced oxidative stress in renal tubular cells through AMPK and cAMP-Epac signal transduction pathways.

Fang F, Liu GC, Kim C, Yassa R, Zhou J, Scholey JW

American journal of physiology. Renal physiology27 Mar 2013Cited by 53 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In renal tubular cells, AICAR mimicked adiponectin's attenuation of ANG II-induced NADPH oxidase activation.

    In plain wordsIn cells, AICAR reduced ANG II-induced NADPH oxidase activation, as adiponectin did.

    Outcome
    DecreaseNADPH oxidase activation
    Study

    humann: not reported in source

    Primary renal proximal tubule cells
    Outcome group
    Oxidative stress · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Activation of AMPK with 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) mimicked, while inhibition of AMPK with compound C abrogated, the effect of adiponectin on ANG II-induced activation of NADPH oxidase.
    3 context sentences
    Summary · context
    ANG II-induced NADPH oxidase activation and oxidative stress were attenuated by adiponectin and dependent on adipoR1.
    Summary · context
    Because activation of the renin-angiotensin system (RAS) is a contributor to CKD progression, we tested our hypothesis by studying the interactions between adiponectin and angiotensin II (ANG II) in renal tubular cells.
    Summary · context
    Primary human renal proximal tubule cells expressed both adiponectin receptor 1 and 2 (adipoR1 and R2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.